A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of MM-141 plus
nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone
based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients
with high serum levels of free IGF-1.